Session: 652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster I
Hematology Disease Topics & Pathways:
Research, Epidemiology, Clinical Research, Real-world evidence, Study Population, Human
Objectives: To determine the prevalence of MGUS in a rural Indian population in a community-based setting.
Methods: A cross-sectional study was conducted across 58 agrarian villages/hamlets of a tribal (aboriginals) district and 8 agrarian villages of a Non-Tribal district of Western India spreading over 2299 square miles (sq-mi), as part of SIMPLe (Screening Intervention for Myeloma and Prevention of Lifestyle diseases) study. For the complete study population, demographic details, medical history, and blood samples were collected after a thorough medical examination. Hemograms and serum protein electrophoresis (SPEP) were performed in all individuals. SPEP was performed using on-site capillary zone electrophoresis. Serum immunofixation electrophoresis (SIFE), and biochemistry (liver and renal function tests) were performed for those with abnormal SPEP graphs (those with M spike and those with abnormal bulges in beta-2 or gamma region suspicious of MGUS). Patients with monoclonal protein on SPEP or SIFE were further assessed for any smoldering/ multiple myeloma features. The data was analyzed using JMP ver. 17.2.0.
Results: A total of 10,024 individuals were screened and data was analyzed for 9283 (8527 Tribal + 756 Non-tribal) individuals. The prevalence of MGUS in the study population was 62 (0.66%) and was 1.79% above the age of 55y (62 of 3447w). The median age of individuals with MGUS was 65y (IQR 59-72) with male preponderance. None of the patients satisfied the criteria for smoldering or multiple myeloma using IMWG criteria. The median Hb of the study population was 12g/dL (IQR 11.4-13). Among those with MGUS, the distribution of heavy and light chains was IgG - 83.33%, IgA - 16.67%, with none having IgM/ IgD paraprotein, Kappa – 50%, and Lambda – 50%. Two individuals only had light chain MGUS.
There was no statistically significant difference between the tribal and non-tribal populations (aged >45y) in the incidence of MGUS (1.798% Vs. 1.745%, p=0.78), total protein levels (7.71 vs. 7.19 g/dL, p=0.87) and albumin-globulin ratio (1.54 vs 1.62, p=0.77) with numerically more patients having polyclonal gammaglobulinemia in the tribal population. The low Hb reflected the statistically lower Hb levels in the tribal population (9.1±4.2 Vs. 12.39±1.8g/dL, p-0.021) owing to concurrent hemoglobinopathies (sickle cell/ thalassemia traits).
Conclusion: The prevalence of MGUS in the rural population of Western India is low at 0.66%, rising to 1.79% in individuals over 55 years, predominantly affecting older males, with IgG MGUS being the most common type. There are no significant differences in MGUS prevalence, total protein levels, or Albumin-globulin ratios between tribal and non-tribal populations over 45 years. Our study comprehensively describes the prevalence of MGUS in rural community settings in India. The background prevalence appears to be lower compared to the Western (both USA ~3% and European~5%) population.
Disclosures: Kumar: KITE: Membership on an entity's Board of Directors or advisory committees, Research Funding; Adaptive: Membership on an entity's Board of Directors or advisory committees, Research Funding; MedImmune/AstraZeneca: Membership on an entity's Board of Directors or advisory committees, Research Funding; Merck: Research Funding; Novartis: Research Funding; Roche: Research Funding; Sanofi: Research Funding; Oncopeptides: Other: Independent review committee participation; Takeda: Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Membership on an entity's Board of Directors or advisory committees, Research Funding; Abbvie: Membership on an entity's Board of Directors or advisory committees, Research Funding.